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ABSTRACT
Since 2011, the annual improving outcomes in the treatment of opioid dependence (IOTOD)
meeting has brought together a broad range of primarily European healthcare professionals as
part of an ongoing effort to promote best practice for this particularly vulnerable patient
population. IOTOD, a comprehensive educational initiative, includes the annual Continuing
Medical Education (CME)-accredited IOTOD conference, which is dedicated to measuring practice
change and outcomes resulting from attendance at its educational sessions. Following each
session, delegates are asked to vote for or against incorporating specified changes into their
clinical practice. These “commitments to change” have formed one measure of the effectiveness
and impact of the IOTOD conference. Here, we look at why educational initiatives like the IOTOD
conference are valuable, examine our methods for conducting a CME-accredited event, and
highlight individualised treatment plans and delivery. We examine this approach – increasingly
seen as best practice – as an example of how it may be changing attitudes and eventually
affecting clinical applications in the field of opioid dependence. The measured commitments to
change offer insight into HCPs’ attitudes towards opioid dependence management and show
that attitudes towards individualised treatment plans seem to be progressively positive, with a
general consensus to incorporate psychosocial interventions.
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Introducing opioid dependence and appropriate
interventions
Opioid dependence is a chronic disorder characterised
by craving, physiological withdrawal, increased toler-
ance and persistence of use despite harm caused [1]. It
is associated with considerable morbidity, including
psychiatric disorders, homelessness and, in people who
inject opioids, hepatitis C virus (HCV) and human
immunodeficiency virus (HIV). Opioid use also
increases the risk of opioid overdoses, a common cause
of death among the opioid-dependent population [1,2].
At present, opioid overdoses are a major health
concern worldwide, with 15 million individuals
believed to be at risk and an estimated 69,000 dying
as a result each year [3]. In Europe, there are 1.3
million people at risk and opioids were associated
with the majority of the 8,441 overdose fatalities regis-
tered in 2015, which have been on the rise since
2012 [4].
There is a strong evidence base for treating opioid
dependence with opioid agonist treatment (OAT),
usually either methadone or buprenorphine, together
with psychosocial interventions (PSIs). OAT has been
shown to reduce morbidity, mortality and offending
among those receiving it, and now plays a significant
role in treatment demands and health harms in a
number of European countries [4]. Overdose deaths
are reduced among people who use opioids while
they are in OAT [5,6]. For example, one meta-analysis
showed that the mortality rate of people in methadone
treatment was less than a third of the expected rate in
opioid users out of treatment [4].
Tailoring treatment plans to the needs of individual
patients, their preferences and goals is strongly sup-
ported by guidelines for dependence, with the UK
clinical guidelines on drug misuse and dependence
advising healthcare professionals (HCPs) against
rigidly using the same approach and care plan for
every patient. In addition to treatment plans, treatment
delivery should also be individualised; monitoring
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patients’ symptoms and listening to feedback is key to
this, and in cases where patients do not respond well to
treatment, HCPs may adjust the dose of OAT or switch
to another OAT. PSIs, a crucial component of treat-
ment, should also be individualised, taking into
account a patient’s preferences and achievable goals.
In addition, HCPs may wish to change the frequency of
patient visits and of monitoring [7,8]. Therefore, tailor-
ing care for opioid-dependent patients is recom-
mended at all stages and across all components of
treatment.
It is important to note the existence of other inter-
ventions, in addition to treatment, which aim to reduce
opioid-related harm and overdoses (Figure 1). Examples
of these include the distribution of naloxone, an opioid
overdose reversal drug, to individuals who are likely to
experience and/or witness an overdose, through take-
home naloxone programmes; in addition, needle and
syringe exchange programmes and supervised drug con-
sumption rooms promote safer injecting practices and a
safe injecting environment, respectively [9]. Despite the
accumulation of evidence that these interventions
reduce opioid-related harms and mortality, their imple-
mentation has been considerably limited worldwide.
Principles underlying continuing medical education
best practice
PCM Scientific is the medical education and continu-
ing medical education (CME) company acting as the
secretariat for IOTOD, with a long track record in
running European CME initiatives that deliver measur-
able outcomes.
PCM Scientific is a founding member of the Good
CME Practice group (gCMEp) that works to establish
and raise standards in the provision of CME in Europe.
The gCMEp has defined and validated the standards of
good CME practice along with four core principles,






As a CME provider, PCM Scientific aims to contribute
to improving public health outcomes by championing
best practice in CME, maintaining and improving stan-
dards and collaborating with stakeholders. This is done
out of a belief that CME is a positive and influential
force for change in clinical practice.
A number of recent studies in the area of opioid
management have shown the effect that CME can have.
McCalmont and colleagues were able to show that
higher hours of recent CME positively benefited pro-
vider confidence in pain management and use of
Centers for Disease Control and Prevention (CDC)-
recommended practices [11]. Another found that by
educating surgeons at an institution in the US [12],
Figure 1. Interventions to reduce the risk of opioid-related deaths require a constellation of efforts. Figure from European
Monitoring Centre for Drugs and Drug Addiction (2017), Health and social responses to drug problems.
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they were able to decrease the number of opioids
initially prescribed post-operatively by just over half.
Information was presented about variability and over-
prescription of opioids and recommendations were
made on the number of opioid pills that should be
prescribed for specific operation types. As well as
demonstrating the potential of CME in general, this
also shows that early educational interventions could
have important implications in future opioid use.
About IOTOD
Improving Outcomes in the Treatment of Opioid
Dependence (IOTOD) is an educational initiative,
organised and developed by PCM Scientific since
2011, that aims to improve patient care in the field of
opioid dependence. This is primarily achieved through
the CME-accredited annual IOTOD conference, which
explores the most pressing challenges faced by the
opioid-dependent population and emphasises the
importance of individualising care. In addition to the
stand-alone conference, IOTOD now includes online
education, such as webcasts, reports and the take-home
naloxone (THN) toolkit.
The IOTOD conference has become a key event in
the opioid dependence therapy sphere owing to its
impactful learning experiences and range of clinically
relevant, advanced, cutting-edge topics discussed at the
annual event. The delegates, mostly HCPs, have also
benefited from the conference’s interactive technology
since 2011. This interactive element has increased dis-
cussions with the speakers and allowed PCM Scientific
to document the changes that delegates have com-
mitted to implementing in their clinical practice, also
known as the IOTOD “commitments to change.”
Here, we reflect on IOTOD delegates’ commitments
to change since 2011 and consider these as markers of
the potential effectiveness of PCM Scientific’s educa-
tional methods. Although the IOTOD conference dis-
cusses a range of topics, here we have focused on
attitudes towards individualised treatments and inte-
grated PSIs as these have been consistent themes since
commitments to change were first recorded in 2011.
Methods
As the secretariat, PCM Scientific undertakes the orga-
nisational work for the conference, incorporating needs
assessments, speaker recruitment, topic selection, logis-
tical support, delegate practice change assessment,
report creation and website hosting/curation.
To reflect the ever-changing field of opioid depen-
dence, the IOTOD conference programme evolves
year-on-year. The programme content is put together
following a comprehensive needs assessment
comprising:
● The previous year’s delegates’ expressions of
interest and needs
● The chairs’ opinions on the most pressing issues
● Practice gaps identified by the chairs and litera-
ture searches
● Relevant upcoming legislation changes and pro-
duct availabilities
● Recently published research that has the potential
to change practice
● New clinical guidelines
The sessions are delivered in an engaging format in
order to drive change in participant behaviours:
● Plenary education sessions
● Complex case studies
● Expert panel discussions
● Interactive audience response system (ARS) tech-
nology throughout
● Commitment-to-change manifesto driven by
delegates’ submissions of what they wish to
change in their day-to-day practice as a result of
what they learned during the sessions
Furthermore, enduring materials from the conferences,
such as highlights reports and webcasts, are hosted on the
IOTOD website (http://www.iotodeducation.com/) and
distributed to relevant databases for an increased reach.
A learning objective is always set ahead of time for
each speaker’s presentation and they are usually
aligned with the commitments to change. Learning
objectives for IOTOD have been routinely created by
leading with a measurable verb, such as those described
in Bloom’s taxonomy of measurable outcomes [13].
Examples of learning objectives used at IOTOD to
date are shown below.
“Following this presentation, participants should be
able to:
● Formulate recovery-orientated treatment plans for
all patients, from the outset of care
● Identify the importance of combining or sequen-
cing psychological interventions with pharmaco-
logical interventions as best practice
● Recognise the importance of post-withdrawal care
and link their patients to appropriate services”
Delegate assessment data are collected during and after
the conference. Data are collected on-site through the
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use of slide show questions after each session, with
delegates answering via voting handsets.
Evaluation comprises:
● On-site – during each of the presentations in the
session: a brief assessment of the baseline level of
learner knowledge and self-reported current prac-
tice (via the ARS)
● On-site – at the end of the conference: attendees
pledge their commitment to change their clinical
practice as a result of attending each session (via
the ARS), agreeing to specific change targets that
are compiled and circulated as the commitment-
to-change manifesto
● Post-meeting evaluation timepoints have varied
historically, but are usually completed at 6 months
and 1 year after the conference – attendees are
asked to participate in an online survey based on
their commitment to change, which assesses any
changes in physician performance that have
occurred as a result of the session
Unlike the online survey, data for the percentage of
delegates responding to the interactive questions or
commitments to change using the ARS on-site are
not available.
Cut-offs for commitments to change were assigned
as follows:
● Commitment accepted, ≥70% agreement
● Commitment rejected, ≤69% agreement
For the purpose of this publication, data were taken
from archived material from 2011 to 2017 focusing on
any commitment to change that involved an integrated
approach to the treatment of opioid dependence
(sometimes historically referred to as medication-
assisted treatment [MAT]). IOTOD did not take place




Most attendees identified themselves as a general prac-
titioner (GP)/family physician, psychiatrist or, in later
years, as an addictions specialist doctor (Table 1).
Attendee geography: most delegates were from the
UK (33%), France (15%) and Germany (12%), with
small percentages from Ireland, Italy, Croatia,
Belgium, Turkey and the USA, and 7% from the rest
of the world.
Commitments to change: general attitudes towards
individualised treatment
Individualised treatment has been a major theme
throughout the 7 years of IOTOD’s commitments to
change. In 2013, 90% of the IOTOD delegates agreed
that treatments should be individualised by adapting
interventions to treatment response, and 91% agreed
that medication should be individualised and guided by
assessment and review.
This call to action increased in 2015 and 2016, when
98% and 97% of the delegates, respectively, committed
to individualising treatment planning and delivery for
both medication and non-medication therapies
(Table 2).
Furthermore, a one-year follow-up survey with
attendees from IOTOD 2016 showed 100% of respon-
dents reported that they now use an individualised
treatment approach in their daily practice.
Commitments to change: review and optimisation
of treatment
Delegates attending the IOTOD conference have con-
sistently supported optimising medication during dif-
ferent phases of treatment. In 2011, 96% of attendees
Table 1. Summary of attendee profession 2011–2017.
2011 2012 2013 2015 2016 2017 Total Total (%)
Psychiatrist 50 125 65 20 44 60 364 27.0
GP 43 118 55 21 23 52 312 23.1
Addictions
specialist
– – – 110 75 92 277 20.5
Nurse 9 19 10 11 21 36 106 7.9
Othera 50 96 42 8 47 27 270 20.0
Psychologistb – – – – 2 1 3 0.2
Pharmacistb – – – – 9 5 14 1.0
Pain
specialistb
– – – – 2 1 3 0.2
152 358 172 170 223 274 1349
aOther also includes medical assistants, psychosocial workers and industry
professionals.
b Breakdown of “Other” unavailable for 2011, 2012, 2013 and 2015, which
included pharmacists, pain specialists and psychologists.
Table 2. Level of participant agreement for individualising
treatment.
Commitment to change Year
Agreement
(%)
Treatments should be individualised by adapting
interventions according to treatment response
and patient goals
2013 90
Medication should be individualised and guided by
assessment and review
2013 91
Individualise treatment planning and delivery
including pharmaceutical and non-
pharmaceutical therapies
2015 98
Individualise treatment planning and delivery,
including pharmaceutical and non-
pharmaceutical therapies
2016 97
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committed to monitoring and assessing therapeutic
dosing of maintenance medication based on patients’
clinical response. The same sentiment was echoed in
2017, with 99% committing to adjusting doses accord-
ing to individual patients’ signs, symptoms and perso-
nal feedback (Table 3).
In a 3-month follow-up survey, which was circulated
to all attendees of IOTOD 2017, 25% of respondents
had implemented this, 69% said that they were already
doing it and the remaining 6% said that they intended
to implement it in the future. Of note, none of the
respondents said they were unable to implement this
change or did not intend to.
In 2011, 100% of IOTOD attendees responding on-site
committed to review each of their patients’ treatment. In
2013, 88% of attendees agreed that clinicians should be
trained to transition between appropriate treatments and
in 2016, 92% of participants committed to make a larger
selection of treatments available to patients (Table 3).
Commitments to change: provision of PSIs
Incorporating PSIs into patients’ treatment plans has
consistently been supported by IOTOD delegates, with
97% agreeing that PSIs should be used alongside opioid
pharmacotherapy in 2011 and in 2017, 97% committed
to incorporating PSIs in the treatment plans of all
opioid-dependent patients (Table 4).
In 2017, 98% of delegates committed to encourage all
their opioid-dependent patients actively to participate in
psychosocial therapies. From a 3-month follow-up survey,
76% said they currently incorporate psychosocial thera-
pies in the treatment plans of their opioid-dependent
patients, and 69% said they now encourage all their
opioid-dependent patients actively to participate in psy-
chosocial therapies. Those who had not implemented the
commitments at the time of the survey, all answered that
they intended to implement them in the future.
While agreement to incorporate PSIs has remained
relatively consistent, there was variation over which
type of behavioural intervention to incorporate. In
terms of cognitive behavioural therapy (CBT), 84% of
delegates agreed to introduce or scale up CBT in their
routine clinical practice in 2015, and in 2016, 83%
agreed to explore CBT with suitable patients; this
increased to 97% in 2017.
In a three-month follow-up survey following the
IOTOD 2016 conference, 33% confirmed they were
currently exploring CBT with suitable patients, 33%
said that they were not doing this and 33% said that
they were unable to; in the 1-year follow-up survey,
39% of respondents said that they had increased the
use of CBT with relevant patients.
Commitments to change: post-meeting response
rates
A representation of the response rate seen with the
post-meeting follow-up surveys:
IOTOD 2016 at three months: 27%
IOTOD 2016 at one year: 14%
IOTOD 2017 at three months: 12%
IOTOD 2017 at one year: 12%
Discussion
Commitments to change: general attitudes towards
individualised treatment
The results show a high proportion of delegates agree
with individualising treatment plans (≥90%) and sup-
port for this has increased (90–98%) over the seven-
year period. These consistent commitments to change
results indicate a trend in favour of personalising treat-
ment at all stages of a patient’s journey, highlighting
the critical importance of this ongoing process to
improve patient outcomes and mirroring the wider
trend towards this approach in clinical practice
Table 3. Level of participant agreement for reviewing and
optimising treatment.
Commitment to change Year Agreement (%)
Monitor/assess therapeutic dosing of
maintenance medication based on clinical
response
2011 96
Periodically review each patient’s treatment 2011 100
Clinicians should be skilled at selecting and
transitioning between treatments
2013 88
Review available MATs; where possible, increase
selection offered to my patients
2016 92
Adjust MAT doses according to patients’ clinical
signs, symptoms and personal feedback
2017 99
Table 4. Level of participant agreement for providing psycho-
social care.
Commitment to change Year
Agreement
(%)
Ensure case management and psychosocial
interventions alongside opioid pharmacotherapy
2011 97
Introduce or scale up: use of contingency
management
2015 83
Introduce or scale up: use of cognitive behavioural
therapy (CBT) in routine clinical practice
2015 84
Explore CBT with relevant patients 2016 83
Introduce or scale up positive rewards to reinforce
positive behaviours
2016 70
Introduce or scale up provision of psychosocial
therapies such as CBT
2016 97
Incorporate psychosocial therapies in the treatment
plans of all of my opioid-dependent patients
2017 97
Motivate all of my opioid-dependent patients to
actively participate in psychosocial therapies
2017 98
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guidelines, such as the UK clinical guidelines for drug
misuse and dependence [7]. Furthermore, positive
results from the IOTOD 2016 1-year follow-up survey
suggests the commitment to individualising treatment
plans was durable.
Commitments to change: review and optimisation
of treatment
The commitments to change regarding reviewing and
optimising treatment were consistently positive and
illustrate an overall readiness of HCPs to commit reg-
ularly to reviewing and optimising the therapeutic dos-
ing of medication based on clinical parameters and
patient-reported symptoms. The data also suggest that
HCPs generally wish to be competent at successfully
transitioning between treatments.
Commitments to change: provision of PSIs
Implementing PSIs together with pharmacotherapy is a
common evidence-based and guideline-recommended
strategy for managing opioid dependence [7,14]. The
IOTOD data highlight strong support for the inte-
grated use of PSIs (97–98% agreement). According to
the 2016 and 2017 follow-up surveys, more than one
third of respondents said that they were either cur-
rently implementing at least one form of PSI or intend-
ing to do so.
Educational outcomes and potential for
improvement
PCM Scientific believes that the format and content of
the IOTOD conference have driven substantial and
sustainable performance improvements. However, a
commitment to the principles of CME means continu-
ally aiming to improve assessment methods, commu-
nication, reach and relevance. IOTOD already offers
scholarships, providing free registrations, in part to
improve accessibility to HCPs that may not otherwise
be able to attend.
IOTOD educational materials and conferences cur-
rently satisfy levels 1 (participation), 2 (participant
satisfaction), 3A (learning declarative knowledge) and
3B (learning procedural knowledge) of Moore’s
expanded outcomes framework for assessing learners
and evaluating instructional activities, as well as sub-
jective measurements (self-reported) for level 4 (com-
petence) and 5 (performance). However, they do not
gather objective measurements (observing competence
or performance) for levels 4 and 5 or measure changes
in level 6 (patient health outcomes) and 7 (community
health) [15], the possibility of obtaining information
pertaining to these is a potential avenue for
improvement.
It is becoming more accepted that passive educa-
tional information dissemination is largely ineffective,
rather, a multifaceted behaviour change strategy is
more powerful. Additionally, audit and feedback pro-
cesses can potentially have a reinforcing effect, as well
as providing valuable information on delegates’ opi-
nions [16]. Future approaches for building on the
methods of learning offered include the use of simula-
tion-based medical education (SBME). SBME has been
shown to enhance retention of training information
compared with lectures [17], and could be incorpo-
rated into the event.
Although the post-meeting assessment response
rates reported here may seem low, typical response
rates for online surveys reported elsewhere are similar.
A recent study attempting to evaluate the impact of a
low-cost non-monetary incentive and paper mail
reminders on response rates for internet-based physi-
cian surveys found that of 3,966 physicians surveyed,
their response rates ranged from 9% to 11.6%[18].
Perhaps novel methods of post-conference response
collection could improve on this in the future.
Finally, the role of the IOTOD educational platform
is currently limited to practising HCPs; however, an
exploration of how to influence the incorporation of
opioid dependence education into undergraduate
teaching could potentially have a wider impact on:
(1) Identifying patients at risk
(2) Recognising signs and symptoms of opioid
dependency
(3) Following proper opioid prescription guidelines
(4) Identifying systems-based practice for referral of
patients who are dependent on opioids
This would more effectively prepare future HCPs to
respond to more situations, manage care and prevent
overdoses [17].
Limitations
This study has a number of limitations regarding the
robustness of the data. Despite the same themes being
explored year to year, these were not accompanied by
identical commitments to change, therefore conclusive
trends in attitudes and practice cannot be drawn. Other
limitations include the changing samples, as the attending
delegate list varies each year. Furthermore, the sample
sizes for on-site commitments to change assessment are
small and the on-site response rates of attendees are
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unavailable, so the results do not represent the whole
opioid dependence healthcare community. Although the
follow-up assessment rates are comparable with other
online questionnaire response rates for HCPs, the fact
that only a small proportion of delegates complete the
follow-up assessments means that this sample may not
be representative of the conference attendees as a whole,
which might also lead to sampling and convenience bias,
distorting the result outcomes. Finally, all assessments are
self-reported and, as such, do not capture real-world
behavioural changes. Our results can only be viewed as
circumstantial observations and should be interpreted
with caution.
Conclusion
The data indicate that HCPs attending the IOTOD
conference are supportive of individualised treatment
planning and delivery, and follow-up surveys suggest
that attendees are motivated to adhere to their com-
mitments in the medium to long term. Notably, dele-
gates were in agreement to review and monitor
therapeutic medication doses and treatment types and
incorporate PSIs into treatment plans.
As IOTOD approaches its ninth year as a CME-
accredited conference, we appreciate the important
role that it has in the continuing education of HCPs
involved in opioid dependence across Europe, and in
providing comprehensive insight and commentary into
the latest advances in the field. Throughout its history,
the IOTOD conference has evolved beyond conven-
tional CME conferences in this area and by harnessing
multi-format educational interventions and behaviour
change techniques, IOTOD is potentially influencing
physician behaviours in an enduring way.
The multidimensional IOTOD educational format
not only enhances delegates’ knowledge but inspires
them to reflect on their practice and commit to making
changes when they return to their daily practices. The
convention of following up with delegates using online
surveys not only allows us to gain insight into the
effectiveness of the education in driving sustainable
changes to clinical practice, but also potentially rein-
forces the intention to commit to the changes.
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